Zacks Investment Research downgraded shares of Recro Pharma (NASDAQ:REPH) from a hold rating to a sell rating in a research report released on Tuesday.
According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “
REPH has been the subject of a number of other research reports. Oppenheimer reaffirmed a buy rating on shares of Recro Pharma in a report on Thursday, April 5th. ValuEngine raised shares of Recro Pharma from a sell rating to a hold rating in a report on Thursday, March 1st. UBS started coverage on shares of Recro Pharma in a report on Tuesday, February 13th. They set an outperform rating for the company. Berenberg Bank started coverage on shares of Recro Pharma in a report on Thursday, April 19th. They set a buy rating for the company. Finally, CIBC started coverage on shares of Recro Pharma in a report on Wednesday, February 14th. They set an outperform rating and a $19.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $14.21.
Recro Pharma stock opened at $10.75 on Tuesday. The company has a debt-to-equity ratio of 2.20, a current ratio of 1.78 and a quick ratio of 1.55. Recro Pharma has a 12 month low of $10.58 and a 12 month high of $11.19.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.03. The firm had revenue of $19.54 million during the quarter, compared to the consensus estimate of $17.32 million. Recro Pharma had a negative net margin of 74.85% and a negative return on equity of 105.78%. equities research analysts predict that Recro Pharma will post -4.09 EPS for the current fiscal year.
In other news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the business’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $10.07, for a total transaction of $2,014,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 20.90% of the company’s stock.
A number of hedge funds have recently bought and sold shares of REPH. Sphera Funds Management LTD. acquired a new stake in Recro Pharma in the first quarter worth about $4,010,000. Lyon Street Capital LLC acquired a new stake in Recro Pharma in the fourth quarter worth about $3,362,000. Millennium Management LLC acquired a new stake in Recro Pharma in the first quarter worth about $3,060,000. The Manufacturers Life Insurance Company lifted its holdings in Recro Pharma by 6,480.5% in the first quarter. The Manufacturers Life Insurance Company now owns 235,712 shares of the specialty pharmaceutical company’s stock worth $2,595,000 after purchasing an additional 232,130 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Recro Pharma by 130.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 187,364 shares of the specialty pharmaceutical company’s stock worth $2,063,000 after purchasing an additional 106,095 shares during the period. 58.49% of the stock is owned by institutional investors and hedge funds.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Get a free copy of the Zacks research report on Recro Pharma (REPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.